Markets

VWR Corp Looks Good on Strategic Initiatives: Add to Portfolio

On Nov 9, 2015, we issued an updated research report on VWR CorporationVWR , an independent worldwide provider of products, services and solutions to laboratory and production facilities.

VWR reported in-line earnings in third-quarter 2015, while revenues managed to beat the Zacks Consensus Estimate. Although severe currency related headwind resulted in a year-over-year decline in revenues, supported by several recent strategic initiatives, the company showed balanced growth in the Americas and EMEA-APAC organically and at CER.

VWR's Americas segment is experiencing an increase in comparable net sales buoyed by several strategic initiatives implemented in recent times. This includes a series of steps undertaken to significantly upgrade its information technology infrastructure, optimize its U.S. distribution network and modify its marketing strategy.

In the reported quarter, the Americas exhibited solid sequential uptrend representing the sixth consecutive quarter of organic revenue growth on continued strength in biopharma.

On the other hand, despite the ongoing weakening of the euro and other currencies, which continue to weigh on the company's EMEA-APAC results, revenues grew 4.2% at CER and 2.9% on an organic basis in the third quarter. Sales to biopharma customers increased in high single digits with significant strong growth in biotech. Production Chemicals continued to exhibit a solid performance while sales to healthcare customers increased in low single digits.

We are also encouraged by the company's healthy customer base and stable liquidity position. However, the continued year-over-year strengthening of the dollar versus the euro has severely hit VWR's international business over the past few quarters. In addition, margin pressure and competitive landscape are major downsides.

Currently, VWR carries a Zacks Rank #2 (Buy).

Key Picks in the Sector

Some other stocks that warrant a look in the broader medical space are Diadexus, Inc. DDXS , Nxstage Medical, Inc. NXTM and SurModics, Inc. SRDX . All the three stocks also sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

SURMODICS (SRDX): Free Stock Analysis Report

DIADEXUS INC (DDXS): Free Stock Analysis Report

NXSTAGE MEDICAL (NXTM): Free Stock Analysis Report

VWR CORP (VWR): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SRDX

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More